Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Eli Lilly announced plans to manufacture its new weight loss pill, orforglipron, in the U.S., with global distribution set to begin in 2026, Bloomberg reported April 18. The move comes as President ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

The results could be harmful to them in more ways than one. Despite this issue, Eli Lilly remains a top stock to buy. As everyone who follows equity markets knows, stocks are feeling the heat from ...

If you're a fan of Gundam, now is the time to lock in your preorder for these brand-new model kits and figures. Whether you're searching for a fresh new Gundam model kit to adorn your collection ...

April 8 - Eli Lilly (NYSE:LLY) shares rose about 5% Tuesday morning after Goldman Sachs (NYSE:GS) upgraded the pharmaceutical giant to Buy from Neutral, citing confidence in its leadership in the fast ...

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

The tool kit may be the oldest intact weapon system found in North America, writes Louie Bond for Texas Parks and Wildlife magazine, which first reported the story. “We were just stunned ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for central nervous system (CNS) diseases. The deal gives Lilly an exclusive ...

They were all involved in the development of the now-famous drugs manufactured by Novo Nordisk and Eli Lilly. Drucker and three co-winners made discoveries about glucagon-like peptide-1 in their labs.

Eli Lilly & Co.’s shares fell Monday morning after the Trump administration spiked a plan late last week to pay for obesity drugs for Medicare patients. The Centers for Medicare and Medicaid ...